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ABSTRACT
In total, 881 presumptive clinical isolates of Streptococcus pneumoniae collected from throughout The
Netherlands were analysed to determine their mechanisms of macrolide resistance. Isolates were
identiﬁed initially by participating laboratories using their own standard identiﬁcation technique,
followed by determination of MICs with Etests. Only 797 isolates were conﬁrmed as pneumococci
following bile-solubility tests, lytA PCR and 16S rRNA sequencing. Of these conﬁrmed pneumococci,
59 (7.4%) isolates were macrolide-resistant. Analysis by PCR indicated that 34 (57.6%) isolates
harboured only the erm(B) gene and 16 (27.1%) only the mef gene. Three (5.1%) isolates carried both
erm(B) and mef, while six (10.2%) isolates were negative for both mechanisms. Of the six negative
isolates, three had a mutation in the 23S rRNA gene, and three were negative for all mechanisms
tested. No isolates with the erm(A) subclass erm(TR) gene were detected. Among the 19 mef-positive
isolates, 14 (73.7%) carried the mef(A) gene, and only ﬁve (26.3%) carried the mef(E) gene. No
linezolid cross-resistance or multiresistance (resistance to more than two classes of antibiotics) was
observed.
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INTRODUCTION
In recent decades there has been a substantial
increase worldwide in penicillin- and macrolide-
resistant pneumococci. In Spain and Hungary,
> 50% of Streptococcus pneumoniae isolates are
resistant or intermediately resistant to penicillin
[1,2], and > 30% of isolates are resistant to macro-
lides [3]. In The Netherlands, although penicillin
resistance is still low (< 1%) [4,5], there is accumu-
lating evidence for an increase in macrolide resist-
ance [6,7]. Interestingly, resistance seems to be
associated mainly with efﬂux mechanisms [6],
while in many other European countries, such as
France, Belgiumand Spain, target sitemodiﬁcation
by the erm(B) gene is more common [8–11]. Thus, it
seems that the situation in TheNetherlands resem-
bles more closely that found in the USA [12].
The present study examined the in-vitro sus-
ceptibility to macrolides and various other anti-
biotics of S. pneumoniae isolates from more than
half of the medical microbiology laboratories in
The Netherlands. The main aims were to deter-
mine the frequency of resistance to macrolides in
The Netherlands, and to investigate the mecha-
nisms of macrolide resistance. The study deter-
mined the presence of the erm(B), mef and erm(A)
subclass erm(TR) genes, as well as mutations in
23S rRNA genes and alterations in the ribosomal
proteins L4 and L22. In addition, the two variants
of the mef gene were distinguished, namely the
mef(E) gene, found originally in S. pneumoniae,
and the mef(A) gene, identiﬁed originally in
Streptococcus pyogenes [13,14].
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METHODS
Bacterial isolates
Thirty-eight medical microbiology laboratories in The Nether-
lands, distributed throughout the country, participated in the
study (Fig. 1). Each laboratory collected a maximum of 30 S.
pneumoniae isolates in the period December 2001 to April 2002.
Fifteen isolates of clinical relevance were required (e.g.,
isolates from normally sterile samples such as blood; no
isolates from nose swabs), with isolation presumably resulting
in antimicrobial treatment, while the other 15 isolates were
from non-sterile sites, thereby including colonising strains.
Only one isolate ⁄patient was allowed. Initial identiﬁcation of
isolates was done by the participating laboratories, using their
own standard identiﬁcation techniques, which usually inclu-
ded a test for optochin susceptibility as a primary identiﬁca-
tion method, with conﬁrmation, if necessary, by another test
such as bile solubility, Accuprobe (GenProbe, San Diego, CA,
USA), Pneumoslide (BBL Microbiology Systems, Cockeysville,
MD, USA) or API Strep (bioMe´rieux, Marcy L’E´toile, France).
Isolates were stored at ) 70C until required for further testing.
All resistant isolates (see below) and a random sample of the
susceptible isolates were re-identiﬁed at the central laboratory
by lytA PCR and by bile-solubility testing as described
previously [15], with the results conﬁrmed by 16S rRNA
sequencing (see below). Subsequently, all remaining isolates
were identiﬁed by the bile-solubility method.
Molecular identiﬁcation methods
LytA-PCR
Detection of the lytA autolysin gene was performed by a real-
time PCR procedure [16], with minor adjustments to adapt this
assay to a LightCycler FastStart format (Roche, Almere, The
Netherlands).
16S rRNA sequencing
Sequence analysis of part of the 16S rRNA gene was performed
using broad-range PCR primers (5¢-CGGCGTGCCTAATA-
CATGC-3¢ and 5¢-CGTATTACCGCGGCTGCT-3¢) to amplify a
variable region at the 5¢-end of the 16S rRNA gene. PCR mixes
contained 0.5 lM primers, 1.5 mMMgCl2, 0.2 mM dNTPs, 1 U
of HotGoldStar DNA polymerase (Eurogentec, Seraing, Bel-
gium), 1· reaction buffer and 2 lL of DNA extract in a total
volume of 50 lL. Cycling conditions comprised 10 min at
94C, followed by 35 cycles of 30 s at 94C, 30 s at 56C and
1 min at 72C, with a ﬁnal extension period for 10 min at 72C.
PCR products were puriﬁed using High-Pure chemistry
(Roche, Almere, The Netherlands) and sequenced on a
Megabase 500 automated DNA analysis platform as recom-
mended by the manufacturer (Amersham Biosciences, Roos-
endaal, The Netherlands). The sequences obtained were
compared to sequences in public databases with the web-
based BLAST interface [17].
MIC determination
All isolates (0.5· McFarland standard) were tested by the
participating laboratories on Mueller–Hinton agar containing
sheep blood 5% v ⁄v with Etests (AB-Biodisk, Solna, Sweden)
for penicillin G, cefotaxime, levoﬂoxacin, moxiﬂoxacin, eryth-
romycin, clarithromycin, telithromycin, clindamycin, linezolid
and vancomycin. Incubation (no additional CO2) was for 24 h
at 37C. Each participating laboratory included control strain
S. pneumoniae ATCC 49619 in each batch of tests, according to
NCCLS guidelines [18]. All MICs for resistant isolates were
conﬁrmed by standardised Etests in the central laboratory.
Identiﬁcation of macrolide resistance genes
Macrolide resistance genes erm(B), mef(A) and mef(E) were
identiﬁed according to the method of Sutcliffe et al. [19] with
minor modiﬁcations. The erm(A) subclass erm (TR) gene was
detected as described by Reinert et al. [20]. 23S rRNA gene
mutations and alterations in the L4 and L22 proteins were
identiﬁed by PCR-based methods that have been described in
detail elsewhere [21]. Resistance phenotypes were determined
by clindamycin susceptibility tests.
Statistical analyses
The Fisher test, Mann–Whitney U-test or Wilcoxon matched-
pairs test were used, as appropriate, to compare groups. A
p value of < 0.05 was considered to be signiﬁcant.
RESULTS
Identiﬁcation of bacterial isolates
Of 963 isolates collected initially, 82 were not
available for retesting and were excluded from
further analysis. Of the remaining 881 isolates, all
resistant isolates (n = 122) and a random sample
of 122 susceptible isolates were re-identiﬁed by
Fig. 1. Distribution of the laboratories in The Netherlands
that participated in the study.
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the bile-solubility and lytA PCR methods. All
bile-soluble isolates were lytA-positive (i.e., pneu-
mococci), while all bile-insoluble isolates were
lytA-negative and were considered to be non-
pneumococci. These results were conﬁrmed by
16S rRNA sequencing, which indicated that most
‘non-pneumococci’ isolates were Streptococcus
mitis. Given the high speciﬁcity of bile solubility
in this population, the remaining 637 isolates
were also analysed by the bile-solubility method.
Overall, 84 (9.5%) of the 881 isolates in the study
were considered to be non-pneumococci.
MICs
The cumulative MICs of the ten antibiotics tested
for the 797 conﬁrmed pneumococcal isolates are
shown in Table 1. There were no signiﬁcant
differences in susceptibility between isolates from
deep and superﬁcial clinical sites, so results of
these two groups were pooled. Macrolide resist-
ance (MIC > 2 mg ⁄L) [22] was found in 7.4% of
isolates. Penicillin resistance (MIC > 1 mg ⁄L) was
found in 0.9% and intermediate resistance
(0.06 mg ⁄L < MIC £ 1 mg ⁄L) in 3.4% of isolates.
Almost half (46.8%) of the penicillin-resistant or -
intermediate isolates were also macrolide-resis-
tant; of these, 71.4% were of the MLSB type.
Conversely, 24.1% of the macrolide-resistant iso-
lates showed decreased susceptibility to penicil-
lin. MIC90s were 1.5 mg ⁄L for linezolid (with only
one resistant isolate: MIC 8 mg ⁄L), 1 mg ⁄L for
vancomycin, 0.023 mg ⁄L for cefotaxime,
0.19 mg ⁄L for clarithromycin, 1 mg ⁄L for levoﬂ-
oxacin, 0.38 mg ⁄L for clindamycin, 0.064 mg ⁄L
for telithromycin, and 0.19 mg ⁄L for moxiﬂoxacin
(Table 1).
Although all erythromycin-resistant isolates
were highly susceptible to telithromycin, the
telithromycin MICs were increased in erythromy-
cin-resistant isolates compared to erythromycin-
susceptible isolates (MIC50 ⁄MIC90 0.094 ⁄ 0.75
mg ⁄L vs. 0.032 ⁄ 0.047 mg ⁄L, respectively). Inter-
estingly, telithromycin MICs for the mef-positive
isolates (range, 0.25–1.5 mg ⁄L) were higher than
for the erm(B)-positive isolates (range, 0.023–
0.25 mg ⁄L). No linezolid cross-resistance or
multiresistant isolates (resistant to more than
two classes of antibiotics) were observed.
Macrolide resistance mechanisms
PCR analysis of the 59 macrolide-resistant pneu-
mococcal isolates showed that 34 (57.6%) carried
only the erm(B) gene and 16 (27.1%) only a mef
gene. Three (5.1%) isolates carried both the erm(B)
and mef genes, while six (10.2%) isolates were
negative for both of these genes. Analysis of the
latter six isolates for the erm(A) subclass erm(TR)
gene, 23S rRNA gene mutations and alterations in
the ribosomal proteins L4 and L22 showed that
three isolates had a mutation in the 23S rRNA
gene—A2058G, A2059G and G2057A, respect-
ively—while three isolates were negative for all
mechanisms tested. Among the 19 mef-positive
isolates, ﬁve (26.3%) carried the mef(E) gene,
while 14 (73.7%) carried the mef(A) gene.
Of all macrolide-resistant isolates, six (10%)
showed a phenotype that did not correlate with
the genotype; that is, four erm(B)-positive isolates
were susceptible to clindamycin, while two iso-
lates were mef-positive (and erm(B)-negative) and
resistant to clindamycin.
DISCUSSION
The present study evaluated the in-vitro suscep-
tibility of S. pneumoniae isolates from The Neth-
erlands to macrolides and various other
antibiotics, and analysed the mechanisms of
Table 1. Cumulative susceptibility percentages for the antibiotics tested (MICs, mg ⁄L) against the conﬁrmed isolates of
Streptococcus pneumoniae that were included in the study
Antibiotic Number £ 0.006 0.016 0.032 0.064 0.125 0.25 0.5 1 2 4 8 16 32 64 128‡ 256
Linezolid 794 7 65 98 99.9 99.9 100
Vancomycin 797 7 58 97 100
Penicillin G 796 6 67 93 96 97 98 99 99 100
Cefotaxime 796 6 78 94 97 98 99 100
Erythromycin 794 1 3 17 66 92 93 93 93 93 93 94 95 96 96 100
Clarithromycin 795 2 7 35 85 93 93 93 93 93 94 94 96 96 96 100
Levoﬂoxacin 797 1 20 91 99.6 99.7 99.7 99.7 99.7 100
Clindamycin 797 1 2 9 42 85 96 96 96 96 96 96 96 96 96 100
Telithromycin 793 1 14 63 94 97 97 99 99 100
Moxiﬂoxacin 795 1 7 67 99 99 99.7 99.8 99.9 99.9 100
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macrolide resistance. Inadequate identiﬁcation
may result in overestimation of pneumococcal
resistance [23,24], and the present study found
that 9.5% of the presumptive pneumococcal
isolates were not S. pneumoniae. This may be
explained by a ﬁnding that optochin susceptibil-
ity, which is generally used as a primary identi-
ﬁcation method by laboratories in The
Netherlands, is not sufﬁciently speciﬁc for routine
identiﬁcation of S. pneumoniae [25]. All non-pneu-
mococcal isolates were excluded from the suscep-
tibility analysis presented here.
Erythromycin resistance of S. pneumoniae in The
Netherlands was found to have increased from
3.8% in 1999 [7] to 7.4% in the present survey, but
it is not clear whether this is related directly to
increased use of macrolides. A temporal relation-
ship between macrolide use and the development
of resistance, usually with a delay of 1–2 years,
has been reported previously [7,26,27], but this
relationship may be multifactorial. Penicillin
resistance (MIC > 1 mg ⁄L) still appeared to be
low (0.9%), but intermediate resistance
(0.06 mg ⁄L < MIC £ 1 mg ⁄L) showed a rise to
3.4% (< 1% in 1999), thus representing a four-fold
rise in non-susceptible isolates [28]. In line with
other surveys [24,29,30], erythromycin and peni-
cillin resistance were related strongly, in that
almost half of the isolates with reduced penicillin
susceptibility were also macrolide-resistant, and
nearly 25% of the macrolide-resistant isolates
showed reduced susceptibility to penicillin.
Although telithromycin showed excellent activ-
ity against all pneumococcal isolates, the MICs for
macrolide-resistant isolates were increased in
comparison to macrolide-susceptible isolates,
indicating that resistance to erythromycin inﬂu-
ences the potency of telithromycin. An increased
telithromycin MIC has not been shown to be
clinically relevant [31–33]; in the current study, all
erythromycin-resistant isolates were highly sus-
ceptible to telithromycin, irrespective of the
mechanism of resistance. Although telithromycin
is considered to be a poor substrate for the efﬂux
pump [34], mef-positive isolates had higher telith-
romycin MICs than erm(B)-positive isolates,
which is in agreement with other published data
[35,36], but the mechanism involved is unknown.
Interestingly, three isolates had high levoﬂoxacin
MICs (‡ 32 mg ⁄L). The moxiﬂoxacin MICs for
these three isolates were 1.5, 2 and 8 mg ⁄L,
respectively (results not shown), indicating the
presence of mutations in the DNA gyrase and
topoisomerase IV genes [37].
Macrolide resistance in S. pneumoniae is known
to occur mainly through target site modiﬁcation
and active drug efﬂux. Target site modiﬁcation,
mediated by the erm(B) gene, also causes resist-
ance to lincosamides and streptogramin B antibi-
otics (the MLSB phenotype), and is associated
with high-level macrolide resistance (MIC >
64 mg ⁄L) [38]. Active drug efﬂux, mediated by
the mef gene, confers resistance only to 14- and
15-membered macrolides (the M phenotype), and
is associated with low- to mid-level macrolide
resistance (MICs of 1–32 mg ⁄L) [19]. Mutations in
the erm(A) subclass erm(TR) gene and the 23S
rRNA gene, and alterations in the ribosomal
proteins L4 and L22, have also been shown to
account for macrolide resistance in pneumococci
[3,39–42]. The present study found that 59.3% of
the macrolide resistance phenotypes were of the
MLSB type and 40.7% were of the M type. This is
in contrast to several other European countries,
where efﬂux-mediated macrolide resistance is
uncommon [10,11]. Thus, a recent survey in
France failed to detect M-type resistance in
pneumococci, while > 90% of macrolide-resistant
isolates in Belgium were of the MLSB type [8,9].
However, M-type resistance is predominant in
Germany and Scotland [43,44]. In these latter two
countries, as in The Netherlands, the observed
prevalence of macrolide resistance mechanisms
resembles that found in the USA [12]. It is not yet
clear whether these regional differences in resist-
ance mechanisms can be explained by differences
in selection pressure or by clonal dynamics.
Analysis of the genetic basis of macrolide
resistance revealed three main genotypes, namely
erm(B), mef(A) and mef(E). Only three isolates had
a mutation in the 23S rRNA gene, and no erm(A)
subclass erm(TR) genes or alterations in the
ribosomal proteins L4 or L22 were found. Car-
riage of mef(E) is considered to be typical of
S. pneumoniae, whereas the mef(A) gene was
identiﬁed originally in S. pyogenes [14,45].
Remarkably, the present study found that mef(A)
was far more prevalent than mef(E) (74% vs. 24%,
respectively). It is not clear whether this interest-
ing ﬁnding can be explained by interspecies
transfer from mef(A)-positive S. pyogenes isolates
in the nasopharynx or by clonal spread [44,46,47].
In contrast to Italy, macrolide resistance among
S. pyogenes isolates in The Netherlands is low [48],
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and there are no data on the prevalence of mef(A)
in S. pyogenes isolates. Preliminary epidemiolog-
ical data (results not shown) for macrolide-resist-
ant isolates do not indicate clonal spread of the
mef(A) gene. Six (10%) resistant isolates showed a
phenotype that did not correlate with the geno-
type. This indicates that a clear relationship
between the type of mutation and the level of
macrolide resistance cannot always be found, and
suggests that additional unidentiﬁed mutations
may be involved.
There have been increasing numbers of reports
of macrolide treatment failures in invasive pneu-
mococcal disease [49–52]. In a study of the
elimination rate of pneumococci in macrolide-
treated otitis media, a signiﬁcant difference was
observed between the bacteriological persistence
of susceptible and resistant pneumococcal isolates
[53]. However, the clinical data available cur-
rently are insufﬁcient to determine whether the
increased macrolide resistance of S. pneumoniae is
clinically relevant [52,54]. Additional studies that
examine pneumococcal MICs in combination with
in-vivo pharmacokinetic and pharmacodynamic
values are required.
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